Time BioVentures Invests in Neuralink's $205M Series C Financing

Time BioVentures is pleased to announce that it has invested in Neuralink's Series C funding round of $205 million, joining lead investor Vy Capital, with participation from Google Ventures, DFJ Growth, Valor Equity Partners, Craft Ventures, Founders Fund, and Gigafund.

Other strategic investors in the round include Robert Nelson (Co-Founder of ARCH Venture Partners), Blake Byers (Byers Capital), Sam Altman (Chairman of YC Group and CEO of OpenAI), Fred Ehrsam (Co-founder of Paradigm and Coinbase), and Ken Howery (Co-Founder of PayPal and Founders Fund).

Neuralink has spent the last four years building the first high channel count brain-machine interface intended for therapeutic use in patients. Its first product, the N1 Link, is a 1024 channel device that, once implanted, is completely invisible and transmits data via a wireless connection. The first indication this device is intended is to help people with quadriplegia regain their digital freedom by allowing users to interact with their computers or phones in high bandwidth and naturalistic way. The funds from the round will be used to take Neuralink’s first product to market and accelerate the research and development of future products.

Neuralink was founded by Elon Musk to help those with brain injuries in the near term and reduce AI risk to humanity in the long term. The company’s mission is to develop brain-machine interfaces that treat various brain-related ailments, with the eventual goal of creating a whole-brain interface capable of more closely connecting biological and artificial intelligence.

General Partner D.A. Wallach has previously invested in other Musk-founded companies, including SpaceX, and is excited to help provide strategic guidance to Neuralink as it enters its first-in-human trials and navigates the next few years of FDA approvals.

Original news release: https://neuralink.com/blog/series-c